Growth of Pulmonary Edema Therapeutics To Be Impacted by the Increasing Use of Biomarkers for Disease Diagnosis | Technavio

The market will register an incremental growth of USD 288.99 million between 2019 and 2023

LONDON--()--The report, global pulmonary edema therapeutics market, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share, as well as market segmentation based on type and geography for the forecast period 2019-2023.

To learn more about the global trends impacting the future of market research: Download Free Sample Report

This report on the pulmonary edema therapeutics market includes:

Pulmonary Edema Therapeutics Market Analysis and Forecast 2019-2023: Features

  • Competitive landscape
  • Market segmentation
    • Type
    • Geography
  • Market drivers
  • Market trends
  • Market challenges
  • Five forces analysis
  • Market landscape
  • Market sizing & forecast

Pulmonary Edema Therapeutics Market 2019-2023: Competitive Landscape

  • Vendors covered
  • Vendor classification
    • AbbVie Inc.
    • Bausch Health Companies Inc.
    • Johnson & Johnson Services Inc.
    • Lupin Ltd.
    • Merck & Co. Inc.
    • Mylan NV
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.

Pulmonary Edema Therapeutics Market 2019-2023: Geographic Landscape

  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries

Pulmonary edema therapeutics Market 2019-2023: Type Landscape

  • Cardiogenic pulmonary edema - Market size and forecast 2018-2023
  • Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023

Register for a free trial today and gain instant access to 10,000+ market research reports.
Technavio's SUBSCRIPTION platform

High prevalence of risk factors will drive the pulmonary edema therapeutics market

The growing prevalence of risk factors is one of the key factors driving the growth of the global pulmonary edema therapeutics market. Various risk factors include organ failures, lifestyle habits, trauma, high altitude, and infections caused by bacteria, viruses, and fungus. The risk factors contribute to the health indication in various ways. For instance, improper functioning of kidneys reduces the elimination of waste fluids, causing fluid overload and accumulation in the lungs.

Increasing use of biomarkers for disease diagnosis – An emerging trend in pulmonary edema therapeutics market

The use of biomarkers has increased over recent years to detect pulmonary edema, which is one of the key pulmonary edema therapeutics market trends. Cardiac markers such as serum brain natriuretic peptide (BNP), N-terminal-pro BNP (NT-pro-BNP), and plasma CD146 cardiac are used to indicate the congestion of heart failure disease, which causes pulmonary edema. Biomarkers can also be used to detect other associated heart or kidney-related diseases. Moreover, the use of biomarkers is less expensive compared with other evaluation tests, which is increasing patient adherence. These factors will boost the growth of the market during the forecast period.

Other Key Topics Covered in the Report are:

MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2023

Get Full Report: https://www.technavio.com/report/pulmonary-edema-therapeutics-market-industry-analysis

CUSTOMER LANDSCAPE

DECISION FRAMEWORK

DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

MARKET TRENDS

  • Increasing use of biomarkers for disease diagnosis
  • Strategic alliances
  • Increase in funding for research on respiratory diseases

Technavio also offers custom research services providing focused, comprehensive, and tailored research.

For More Information Click Here

Browse Related Healthcare Reports:

  • Global Single-use Airway Diagnostic Devices Market: The single-use airway diagnostic devices market is forecast to grow at a CAGR of over 8% during 2019-2023. The single-use airway diagnostic devices market size will increase by USD 847.96 million during 2019-2023.

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:media@technavio.com

Release Summary

The report, global pulmonary edema therapeutics market, has been added to Technavio’s catalog.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:media@technavio.com